Drug Profile
ZEN 3694
Alternative Names: BETi ZEN-3694; ZEN-003694; ZEN-3694Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator University of Pittsburgh; Zenith Epigenetics
- Developer National Cancer Institute (USA); Pfizer; Zenith Epigenetics
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Carcinoma; Lymphoma
- No development reported Haematological malignancies; Lung cancer
Most Recent Events
- 23 Jan 2024 University of Pittsburgh in collaboration with GSK initiates enrollment in a phase I clinical trial in Solid tumours (Combination therapy, Metastatic disease, Recurrent) in USA (PO) (NCT06161493)
- 06 Dec 2023 Haider Mahdi plans a phase I trial for Solid tumours (Metastatic disease, Second-line therapy or greater, Combination therapy) in the USA (PO) in December 2023 (NCT06161493)
- 18 Jul 2023 National Cancer Institute in collaboration with NRG Oncology plans a phase Ib trial for Ovarian Cancer and Endometrial Cancer (Combination therapy, Recurrent, Second-line therapy or greater) in August 2023 (PO) (NCT05950464)